Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancer

Clinical Epigenetics

Table 1 Protein tumor marker concentrations among the investigated patients with metastatic breast cancer and healthy females

	CA 15-3 (mean ± SE, n = 24)	CEA (mean ± SE, n = 24)	TPA (mean ± SE, n = 24)
Patients with metastatic breast cancer	1552 ± 384 kU/L^a	559.7 ± 177 μg/L^a	2639 ± 657 U/L^a
Age-matched healthy females	14.4 ± 1.1 kU/L	3.1 ± 0.3 μg/L	56.8 ± 10.8 U/L

^aSignificantly different from age-matched control concentration (p < 0.05). The serum samples were used to isolate DNA, which was used to calculate the sensitivity and specificity of six different primer designs against hypermethylated RASSF1A

ISSN: 1868-7083